MCID: LSH001
MIFTS: 66

Leishmaniasis

Categories: Rare diseases, Infectious diseases, Skin diseases

Aliases & Classifications for Leishmaniasis

MalaCards integrated aliases for Leishmaniasis:

Name: Leishmaniasis 12 50 52 41 3 42 14 69
Post-Kala-Azar Dermal Leishmaniasis 12 69
Post-Kala-Azar Dermal Infectious Disease by Leishmaniasis 12
Post Kala-Azar Dermal Leishmaniasis 12
Leishmaniasis, Cutaneous 69
Cutaneous Leishmaniasis 50
Leishmaniasis, Visceral 69
Visceral Leishmaniasis 50
Kala-Azar 50

Classifications:



Summaries for Leishmaniasis

MedlinePlus : 41 leishmaniasis is a parasitic disease spread by the bite of infected sand flies. there are several different forms of leishmaniasis. the most common are cutaneous and visceral. the cutaneous type causes skin sores. the visceral type affects internal organs such as the spleen, liver, and bone marrow. people with this form usually have fever, weight loss, and an enlarged spleen and liver. leishmaniasis is found in parts of about 88 countries. most of these countries are in the tropics and subtropics. it is possible but very unlikely that you would get this disease in the united states. but you should be aware of it if you are traveling to the middle east or parts of central america, south america, asia, africa or southern europe. treatment is with medicines that contain antimony, a type of metal, or with strong antibiotics. the best way to prevent the disease is to protect yourself from sand fly bites: stay indoors from dusk to dawn, when sand flies are the most active wear long pants and long-sleeved shirts when outside use insect repellent and bed nets as needed centers for disease control and prevention

MalaCards based summary : Leishmaniasis, also known as post-kala-azar dermal leishmaniasis, is related to mucocutaneous leishmaniasis and hemophagocytic lymphohistiocytosis, and has symptoms including abnormality of the nose, pallor and splenomegaly. An important gene associated with Leishmaniasis is IL10 (Interleukin 10), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs chloroquine and Primaquine have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and spleen, and related phenotypes are Increased shRNA abundance (Z-score > 2) and hematopoietic system

NIH Rare Diseases : 50 leishmaniasis is a parasitic disease spread by the bite of infected sand flies. there are several different forms of leishmaniasis. the most common are cutaneous and visceral. the cutaneous type causes skin sores. the visceral type affects internal organs such as the spleen, liver and bone marrow. people with this form usually have fever, weight loss, and an enlarged spleen and liver. visceral disease can be deadly without proper treatment. leishmaniasis is found in parts of the middle east, central america, south american, asia, africa, and southern europe. most of these countries are in the tropics and subtropics. it is possible but very unlikely to get this disease in the united states. last updated: 7/6/2011

CDC : 3 Leishmaniasis is a parasitic disease that is found in parts of the tropics, subtropics, and southern Europe. It is classified as a Neglected Tropical Disease (NTD). Leishmaniasis is caused by infection with Leishmania parasites, which are spread by the bite of phlebotomine sand flies. There are several different forms of leishmaniasis in people. The most common forms are cutaneous leishmaniasis, which causes skin sores, and visceral leishmaniasis, which affects several internal organs (usually spleen, liver, and bone marrow).

Disease Ontology : 12 A parasitic protozoa infectious disease that involves infection caused by protozoan parasite of the genus Leishmania, which is transmitted by the bite of sand fly (subfamily Phlebotominae).

Wikipedia : 72 Leishmaniasis is a disease caused by parasites of the Leishmania type. It is spread by the bite of... more...

Related Diseases for Leishmaniasis

Diseases related to Leishmaniasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 424)
id Related Disease Score Top Affiliating Genes
1 mucocutaneous leishmaniasis 31.8 IFNG IFNGR1 IL10 IL4 LMLN NOS2
2 hemophagocytic lymphohistiocytosis 31.1 IFNG IL10 TNF
3 lagophthalmos 30.4 IL10 IL4 TNF
4 melioidosis 29.9 IFNG IL10 TLR2 TLR4 TNF
5 primary biliary cirrhosis 29.8 IL10 IL1A SLC11A1 TNF
6 membranoproliferative glomerulonephritis 29.6 IFNG TLR9 TNF
7 rheumatoid arthritis 28.4 HLA-DRB1 IFNG IL10 IL1A IL1B IL4
8 systemic lupus erythematosus 28.4 HLA-DRB1 IFNG IL10 IL4 ITGAM TLR9
9 lymphoma 28.1 IFNG IL10 IL13 IL1B IL4 IL5
10 malaria 24.1 HLA-DRB1 HSPA4 IFNG IFNGR1 IL10 IL13
11 visceral leishmaniasis 12.5
12 cutaneous leishmaniasis 12.5
13 kala-azar 1 11.2
14 myoclonic astatic epilepsy 11.0 IFNG IL4
15 pure autonomic failure 11.0 IL10 TNF
16 eye accommodation disease 10.9 IFNG IL10 IL4
17 acute ackee fruit intoxication 10.9 IL10 IL4 TNF
18 thelaziasis 10.9 IFNG IL10 IL4
19 basidiobolomycosis 10.9 IL10 IL4 TNF
20 plantar wart 10.9 IFNG IL10 TNF
21 liver leiomyoma 10.9 IL10 IL4 TNF
22 hypercalcinuria macular coloboma 10.8 IFNG IL4 TLR4
23 cyclosporiasis 10.8 IFNG IL10 TNF
24 idiopathic dilatation of the pulmonary artery 10.8 IL10 NOS2 TNF
25 psychologic dyspareunia 10.8 IFNG IL10 TNF
26 dysphagia 10.8 IFNG IL10 TNF
27 phlyctenulosis 10.8 IL10 IL4 TNF
28 conduct disorder 10.8 IFNG IL10 TNF
29 low compliance bladder 10.8 NOS2 TLR4 TNF
30 mosaic trisomy 1 10.8 HLA-DRB1 IFNG TNF
31 rickettsialpox 10.8 TLR2 TLR4 TNF
32 bulbospinal polio 10.8 IFNG TLR4
33 intracranial aneurysms multiple congenital anomaly 10.8 IFNG IFNGR1
34 reardon wilson cavanagh syndrome 10.8 IFNG IL4 TNF
35 antigen-peptide-transporter 2 deficiency 10.8 TLR2 TLR4 TNF
36 chronic rhinitis 10.8
37 cornea cancer 10.8 IFNG IL10 TNF
38 epidermolysis bullosa acquisita 10.8 HLA-DRB1 IFNG IL10
39 burn scar 10.8 IFNG IL10 TNF
40 erythema infectiosum 10.8 IFNG IL4 TNF
41 cryptococcosis 10.8 HLA-DRB1 IL10 TNF
42 sternal cleft 10.7 IFNG IL1B TNF
43 gastroduodenal crohn's disease 10.7 TLR2 TLR4 TNF
44 oropharyngeal cancer, childhood 10.7 IFNG IL10 IL4 TNF
45 spindle cell hemangioma 10.7 IFNG IL10 IL4 TNF
46 moderately severe hemophilia b 10.7 HLA-DRB1 IL10 TNF
47 acute monoblastic leukemia 10.7 IFNG IL10 IL4 TNF
48 orbital osteomyelitis 10.7 IFNG IL10 IL4 TNF
49 plummer's disease 10.7 HLA-DRB1 IL10 TNF
50 vulvar nodular hidradenoma 10.7 IFNG IL10 IL4

Graphical network of the top 20 diseases related to Leishmaniasis:



Diseases related to Leishmaniasis

Symptoms & Phenotypes for Leishmaniasis

Human phenotypes related to Leishmaniasis:

32 (show all 24)
id Description HPO Frequency HPO Source Accession
1 abnormality of the nose 32 hallmark (90%) HP:0000366
2 pallor 32 frequent (33%) HP:0000980
3 splenomegaly 32 hallmark (90%) HP:0001744
4 weight loss 32 frequent (33%) HP:0001824
5 thrombocytopenia 32 occasional (7.5%) HP:0001873
6 pancytopenia 32 hallmark (90%) HP:0001876
7 leukopenia 32 occasional (7.5%) HP:0001882
8 abnormal bleeding 32 hallmark (90%) HP:0001892
9 anemia 32 frequent (33%) HP:0001903
10 episodic fever 32 hallmark (90%) HP:0001954
11 anorexia 32 occasional (7.5%) HP:0002039
12 hepatomegaly 32 hallmark (90%) HP:0002240
13 lymphadenopathy 32 hallmark (90%) HP:0002716
14 arthralgia 32 frequent (33%) HP:0002829
15 elevated hepatic transaminases 32 frequent (33%) HP:0002910
16 hypoalbuminemia 32 frequent (33%) HP:0003073
17 abnormality of macrophages 32 hallmark (90%) HP:0004311
18 increased antibody level in blood 32 frequent (33%) HP:0010702
19 abnormality of oral mucosa 32 hallmark (90%) HP:0011830
20 fatigue 32 occasional (7.5%) HP:0012378
21 night sweats 32 hallmark (90%) HP:0030166
22 papule 32 hallmark (90%) HP:0200034
23 skin plaque 32 hallmark (90%) HP:0200035
24 skin ulcer 32 hallmark (90%) HP:0200042

UMLS symptoms related to Leishmaniasis:


exanthema, fever, pruritus

GenomeRNAi Phenotypes related to Leishmaniasis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.94 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.94 HSPA4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-108 9.94 HSPA4
4 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.94 IL13 HSPA4
5 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.94 IL10 TLR4
6 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.94 TLR4
7 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.94 HLA-DRB1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.94 IL10
9 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.94 IL13 HLA-DRB1 TLR4 HSPA4 IL10
10 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.94 IL13
11 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.94 IL10
12 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.94 HLA-DRB1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.94 IL10
14 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.94 IL10
15 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.94 HLA-DRB1 TLR4 HSPA4
16 Increased shRNA abundance (Z-score > 2) GR00366-A-172 9.94 HSPA4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.94 HLA-DRB1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.94 HLA-DRB1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.94 HLA-DRB1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.94 IL10
21 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.94 IL13
22 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.94 IL10
23 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.94 IL10
24 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.94 TLR4
25 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.94 IL10
26 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.94 IL13
27 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.94 IL10
28 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.94 HSPA4
29 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.94 IL10
30 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.94 HLA-DRB1 IL10
31 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.94 IL10
32 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.94 IL10

MGI Mouse Phenotypes related to Leishmaniasis:

44 (show all 15)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.37 IFNG IFNGR1 IL10 IL13 IL1A IL1B
2 cellular MP:0005384 10.35 HSPA4 IFNG IFNGR1 IL10 IL13 IL4
3 immune system MP:0005387 10.33 TLR2 TLR4 TLR9 TNF IFNG IFNGR1
4 homeostasis/metabolism MP:0005376 10.32 IL4 IL5 ITGAM NOS2 TLR2 TLR4
5 digestive/alimentary MP:0005381 10.3 TLR9 TNF IFNG IFNGR1 IL10 IL13
6 cardiovascular system MP:0005385 10.25 NOS2 TLR2 TLR4 TNF IFNG IFNGR1
7 mortality/aging MP:0010768 10.21 HSPA4 IFNG IFNGR1 IL10 IL13 IL1B
8 integument MP:0010771 10.17 IFNG IFNGR1 IL10 IL13 IL1A IL1B
9 endocrine/exocrine gland MP:0005379 10.16 IFNGR1 IL10 IL13 IL4 NOS2 TLR2
10 liver/biliary system MP:0005370 10.06 IL10 IL4 IL5 NOS2 TLR2 TLR4
11 neoplasm MP:0002006 10.06 IFNG IFNGR1 IL10 IL1A IL1B IL5
12 nervous system MP:0003631 10.03 HSPA4 IFNG IFNGR1 IL10 IL1B IL4
13 reproductive system MP:0005389 9.85 HSPA4 IFNG IFNGR1 IL10 IL13 IL4
14 respiratory system MP:0005388 9.61 TNF IFNG IL10 IL13 IL4 IL5
15 skeleton MP:0005390 9.36 IFNG IFNGR1 IL10 IL13 IL1B IL4

Drugs & Therapeutics for Leishmaniasis

Drugs for Leishmaniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
chloroquine Approved, Vet_approved Phase 4 54-05-7 2719
2
Primaquine Approved Phase 4 90-34-6 4908
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
4
Miltefosine Approved Phase 4,Phase 3,Phase 2,Phase 1 58066-85-6 3600
5
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1397-89-3 14956 5280965
6
deoxycholic acid Approved Phase 4,Phase 3 83-44-3 222528
7
Paromomycin Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 1263-89-4, 7542-37-2 165580
8
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3 137-58-6 3676
9 Analgesics Phase 4,Phase 2,Phase 3
10 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3
11 Anthelmintics Phase 4,Phase 3,Phase 2,Phase 1
12 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
13 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
14 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3
15 Antimalarials Phase 4
16 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Antirheumatic Agents Phase 4,Phase 2,Phase 3
19 Chloroquine diphosphate Phase 4 50-63-5
20 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3
21 meglumine antimoniate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Antimony Sodium Gluconate Phase 4,Phase 3,Phase 2,Phase 1
24 Amphotericin B, deoxycholate drug combination Phase 4,Phase 3
25 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Cholagogues and Choleretics Phase 4,Phase 3
27 Gastrointestinal Agents Phase 4,Phase 3,Phase 1
28 Liposomal amphotericin B Phase 4,Phase 3,Phase 2,Phase 1
29 Anesthetics Phase 4
30
Ethanol Approved Phase 2, Phase 3 64-17-5 702
31
Petrolatum Approved Phase 2, Phase 3 8009-03-8
32
Salicylic acid Approved, Vet_approved Phase 2, Phase 3 69-72-7 338
33
Pentoxifylline Approved, Investigational Phase 2, Phase 3 6493-05-6 4740
34
Pentamidine Approved Phase 3,Phase 2 100-33-4 4735
35
Imiquimod Approved, Investigational Phase 3,Phase 2 99011-02-6 57469
36
Aluminum sulfate Approved Phase 2, Phase 3, Phase 1 10043-01-3
37
Nitric Oxide Approved Phase 3 10102-43-9 145068
38
Azithromycin Approved Phase 2, Phase 3 83905-01-5 55185 53477736 447043
39
Fluconazole Approved Phase 3 86386-73-4 3365
40
Calcitriol Approved, Nutraceutical Phase 2, Phase 3 32222-06-3 134070 5280453
41
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
42
Niacin Approved, Investigational, Nutraceutical Phase 2, Phase 3 59-67-6 938
43
Nicotinamide Approved, Nutraceutical Phase 2, Phase 3 98-92-0 936
44 Tocopherol Approved, Nutraceutical Phase 3
45
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
46 Cyclooxygenase Inhibitors Phase 2, Phase 3
47 Dermatologic Agents Phase 2, Phase 3
48 Keratolytic Agents Phase 2, Phase 3
49 Pharmaceutical Solutions Phase 2, Phase 3
50 Salicylates Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 144)

id Name Status NCT ID Phase Drugs
1 Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan Unknown status NCT01178021 Phase 4 Chloroquine;Chloroquine/Primaquine
2 Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis Completed NCT00317980 Phase 4 Meglumine antimoniate;Meglumine antimoniate
3 Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children Completed NCT01032187 Phase 4 Meglumine antimoniate;Amphotericin B-deoxycholate
4 Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients Completed NCT00818818 Phase 4 Meglumine antimoniate
5 A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) Completed NCT01975051 Phase 4 Mitefosine
6 Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis Completed NCT00604955 Phase 4 Paromomycin sulfate
7 Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India Completed NCT01661296 Phase 4 Sodium stibogluconate
8 Pharmacokinetics of Miltefosine in Children and Adults Completed NCT01462500 Phase 4 Miltefosine
9 Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh Completed NCT03311607 Phase 4 AmBisome
10 Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis Not yet recruiting NCT01566552 Phase 4 AMBISOME
11 Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil Terminated NCT01310738 Phase 4 Antimoniate of N-methylglucamine;amphotericin B deoxycholate;Liposomal amphotericin B;Liposomal amphotericin B;Antimoniate of N-methylglucamine
12 Oral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia Unknown status NCT00487253 Phase 3 Miltefosine;Meglumine antimoniate
13 Pyruvic Acid Versus Salicylic Acid Preparation in Treatment of Plantar Warts Unknown status NCT02151630 Phase 2, Phase 3 Pyruvic acid;Salicylic Acid
14 An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis Completed NCT00629031 Phase 3 Paromomycin;Paromomycin
15 Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis Completed NCT01381055 Phase 2, Phase 3 Pentoxifylline;Placebo
16 To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar Completed NCT00876824 Phase 3 Amphotericin B Lipid emulsion;Liposomal Amphotericin B
17 Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis Completed NCT00628719 Phase 3 Liposomal Amphotericin B;amphotericin B deoxycholate
18 Liposomal Amphotericin in Disseminated Leishmaniasis Completed NCT02025491 Phase 3 Liposomal Amphotericin B
19 Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis Completed NCT01464242 Phase 2, Phase 3 Meglumine antimonate;Placebo;Pentoxifylline
20 Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia) Completed NCT00606580 Phase 3 WR 279,396 topical cream;Paromomycin Alone topical cream;Vehicle placebo cream
21 Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis Completed NCT00216346 Phase 3 Paromomycin sulfate;Amphotericin B
22 Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia. Completed NCT00471705 Phase 3 Miltefosine;Glucantime®
23 Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis Completed NCT00696969 Phase 3 Amphotericin B Deoxycholate;Ambisome + Miltefosine;Ambisome and Paromomycin;Miltefosine and Paromomycin
24 Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study Completed NCT01360762 Phase 3 Pentamidine
25 Combination Therapy in Indian Visceral Leishmaniasis Completed NCT00523965 Phase 3 amphotericin B deoxycholate;Liposomal Amphotericin B with Miltefosine;Liposomal Amphotericin B and Paromomycin Sulfate;miltefosine + Paromomycin sulfate
26 Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis Completed NCT00257530 Phase 3 Imiquimod
27 Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis Completed NCT00255567 Phase 3 Sodium Stibogluconate;Paromomycin sulphate;SSG and Paromomycin sulphate
28 Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama Completed NCT01790659 Phase 3 WR 279,396;Paromomycin
29 Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica Completed NCT00351520 Phase 3 Miltefose
30 Replacement of Insecticides to Control Visceral Leishmaniasis (VL) Completed NCT01644682 Phase 3
31 Rationale for New Topical Anthroponotic Cutaneous Leishmaniasis (ACL) Treatment in Kabul Completed NCT00947362 Phase 2, Phase 3 DAC N-055;saline
32 Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh Completed NCT01122771 Phase 3 Liposomal amphotericin B;liposomal amphotericin B + miltefosine;liposomal amphotericin B + paromomycin;Miltefosine + Paromomycin
33 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin Completed NCT00429715 Phase 2, Phase 3
34 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0) Completed NCT00429780 Phase 2, Phase 3
35 Clinical Trial for the Treatment of Diabetic Foot Ulcers Using a Nitric Oxide Releasing Patch: PATHON Completed NCT00428727 Phase 3 Controlled nitric oxide releasing patch;placebo patch
36 Nicotinamide in the Treatment of Psoriasis Completed NCT01763424 Phase 2, Phase 3 Calcipotriol plus Nicotinamide;Calcipotriol
37 Low Antimonial Dosage in American Mucosal Leishmaniasis Recruiting NCT01301937 Phase 2, Phase 3 Meglumine antimoniate
38 Miltefosine for Children With PKDL Recruiting NCT02193022 Phase 3 Miltefosine
39 Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis Active, not recruiting NCT01301924 Phase 2, Phase 3 Meglumine antimoniate
40 Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. Active, not recruiting NCT02011958 Phase 3 Liposomal Amphotericin B;Miltefosine
41 Miltefosine and GM-CSF in Cutaneous Leishmaniasis Not yet recruiting NCT03023111 Phase 3 Sbv;Miltefosine plus placebo;Miltefosine plus GM-CSF
42 Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa Not yet recruiting NCT03129646 Phase 3 Miltefosine;Paromomycin;Sodium stibogluconate
43 Effectiveness, Safety and Feasibility of HECT-CL, in Quetta, Pakistan Not yet recruiting NCT03208543 Phase 3
44 Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia Not yet recruiting NCT03096457 Phase 2, Phase 3 Paromomycin Sulfate;Pentamidine Isethionate
45 Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis Terminated NCT00682656 Phase 2, Phase 3 Glucantime®;Zithromax ®
46 High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus Terminated NCT01953744 Phase 3 Fluconazole;Meglumine Antimoniate
47 Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Terminated NCT00317629 Phase 3 controlled nitric oxide releasing patch;meglumine antimoniate
48 Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis Unknown status NCT00840359 Phase 2
49 Short Course of Miltefosine and Antimony to Treat Cutaneous Leishmaniasis in Bolivia Unknown status NCT00537953 Phase 2 Miltefosine , meglumine antimoniate
50 Sodium Stibogluconate Treatment of Leishmaniasis Completed NCT00662012 Phase 2 Sodium Stibogluconate (SSG)

Search NIH Clinical Center for Leishmaniasis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: leishmaniasis

Genetic Tests for Leishmaniasis

Anatomical Context for Leishmaniasis

MalaCards organs/tissues related to Leishmaniasis:

39
Skin, Liver, Spleen, Bone, Bone Marrow, Testes, T Cells

Publications for Leishmaniasis

Articles related to Leishmaniasis:

(show top 50) (show all 2009)
id Title Authors Year
1
Leishmaniasis treatment: update of possibilities for drug repurposing. ( 28930585 )
2018
2
Spatial distribution, Leishmania species and clinical traits of Cutaneous Leishmaniasis cases in the Colombian army. ( 28850603 )
2017
3
Screening of TNFI+, IL-10 and TLR4 single nucleotide polymorphisms in individuals with asymptomatic and chronic cutaneous leishmaniasis in Colombia: a pilot study. ( 28241747 )
2017
4
The new situation of cutaneous leishmaniasis after Syrian civil war in Gaziantep city, Southeastern region of Turkey. ( 27983970 )
2017
5
Historical overview of infantile visceral leishmaniasis in El Agamy, Alexandria, Egypt. ( 28870535 )
2017
6
Cutaneous leishmaniasis in a severely immunocompromised HIV patient in Kumbo, Northwest region of Cameroon: case report. ( 28841834 )
2017
7
Aspects on the Ecology of Phlebotomine Sand Flies (Diptera: Psychodidae) From GuaraA-, State of Tocantins, Brazil, Endemic Area for American Cutaneous Leishmaniasis. ( 28082651 )
2017
8
Hematological Characteristics of Yemeni Adults and Children with Visceral Leishmaniasis. Could Eosinopenia be a Suspicion Index? ( 28894565 )
2017
9
Childhood Visceral leishmaniasis: Distinctive Features and Diagnosis of a Re-Emerging Disease. An 11-Year Experience from a Tertiary Referral Center in Athens, Greece. ( 28938257 )
2017
10
Challenges in modeling complexity of neglected tropical diseases: a review of dynamics of visceral leishmaniasis in resource limited settings. ( 28936226 )
2017
11
Ammonium trichloro [1,2-ethanediolato-O,O']-tellurate cures experimental visceral leishmaniasis by redox modulation of Leishmania donovani trypanothione reductase and inhibiting host integrin linked PI3K/Akt pathway. ( 28900667 )
2017
12
Diagnosis of Mediterranean visceral leishmaniasis by detection of Leishmania-related antigen in urine and oral fluid samples. ( 28017861 )
2017
13
Novel PCR primers to diagnose visceral leishmaniasis using peripheral blood, spleen or bone marrow aspirates. ( 28942823 )
2017
14
Alterations in Evoked Otoacoustic Emissions by the Use of Meglumine Antimoniate in American Tegumentary Leishmaniasis Patients. ( 28045920 )
2017
15
Targeting Prolyl-tRNA Synthetase to Accelerate Drug Discovery against Malaria, Leishmaniasis, Toxoplasmosis, Cryptosporidiosis, and Coccidiosis. ( 28867614 )
2017
16
Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: A first step to assess the feasibility of establishing an individual patient data sharing platform. ( 28873394 )
2017
17
Temporal dynamics and Leishmania infantum infection prevalence of Phlebotomus perniciosus (Diptera, Phlebotominae) in highly endemic areas of visceral leishmaniasis in Tunisia. ( 28934263 )
2017
18
Leech therapy in treatment of cutaneous leishmaniasis: a case report. ( 28844218 )
2017
19
Effect of secondary infection on epithelialisation and total healing of cutaneous leishmaniasis lesions. ( 28902290 )
2017
20
Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble Leishmania antigens and modified with a TNFI+-mimicking peptide or monophosphoryl lipid A confers protection against experimental visceral leishmaniasis. ( 28883727 )
2017
21
Molecular targets and pathways for the treatment of visceral leishmaniasis. ( 28919438 )
2017
22
A Case of Cutaneous Leishmaniasis guyanensis Mimicking Otitis Externa. ( 28811000 )
2017
23
Spatiotemporal and molecular epidemiology of cutaneous leishmaniasis in Libya. ( 28880944 )
2017
24
An Atypical Case of Leishmaniasis Associated with Chronic Duodenitis in a Dog. ( 28282232 )
2017
25
Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme. ( 28066878 )
2017
26
First report on molecular characterization of Leishmania species from cutaneous leishmaniasis patients in southern Khyber Pakhtunkhwa province of Pakistan. ( 28870350 )
2017
27
Reprint of "Spatial modeling of Cutaneous Leishmaniasis in Iran from 1983 to 2013". ( 27914666 )
2017
28
The pulsed dye laser is more effective and rapidly acting than intralesional meglumine antimoniate therapy for cutaneous leishmaniasis. ( 28043177 )
2017
29
Scoring clinical signs can help diagnose canine visceral leishmaniasis in a highly endemic area in Brazil. ( 28076469 )
2017
30
First description of Leishmania (Viannia) infection in Evandromyia saulensis, Pressatia sp. and Trichophoromyia auraensis (Psychodidae: Phlebotominae) in a transmission area of cutaneous leishmaniasis in Acre state, Amazon Basin, Brazil. ( 28076470 )
2017
31
Field trial of efficacy of the Leish-tecAr vaccine against canine leishmaniasis caused by Leishmania infantum in an endemic area with high transmission rates. ( 28953944 )
2017
32
Deforming Mucocutaneous Leishmaniasis of the Nose. ( 28538073 )
2017
33
Effects of Bone Marrow Mesenchymal Stromal Cell Therapy in Experimental Cutaneous Leishmaniasis in BALB/c Mice Induced by Leishmania amazonensis. ( 28848541 )
2017
34
Serological tests fail to discriminate dogs with visceral leishmaniasis that transmit Leishmania infantum to the vector Lutzomyia longipalpis. ( 28954069 )
2017
35
Computational design of molecular motors as nanocircuits in Leishmaniasis. ( 28928941 )
2017
36
Phlebotomines in an area endemic for American cutaneous leishmaniasis in northeastern coast of Brazil. ( 28902258 )
2017
37
Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review. ( 28926630 )
2017
38
Control of visceral leishmaniasis in Somalia: achievements in a challenging scenario, 2013a892015. ( 28945058 )
2017
39
Synthetic peptides derived from ribosomal proteins of Leishmania spp. in mucocutaneous leishmaniasis: Diagnostic usefulness. ( 28758598 )
2017
40
An Anti-Inflammatory Role for NLRP10 in Murine Cutaneous Leishmaniasis. ( 28931602 )
2017
41
Visceral leishmaniasis in two patients with IL-12p40 and IL-12RI^1 deficiencies. ( 27873456 )
2017
42
New insights into experimental visceral leishmaniasis: Real-time in vivo imaging of Leishmania donovani virulence. ( 28945751 )
2017
43
Modeling zoonotic cutaneous leishmaniasis incidence in central Tunisia from 2009-2015: Forecasting models using climate variables as predictors. ( 28841642 )
2017
44
Detection and identification of cutaneous leishmaniasis isolates by culture, Polymerase chain reaction and sequence analyses in Syrian and Central Anatolia patients. ( 28889158 )
2017
45
HIF-1I+ is a key regulator in potentiating suppressor activity and limiting the microbicidal capacity of MDSC-like cells during visceral leishmaniasis. ( 28892492 )
2017
46
The direct costs of treating human visceral leishmaniasis in Brazil. ( 28954068 )
2017
47
Mucosal leishmaniasis mimicking T-cell lymphoma in a patient receiving monoclonal antibody against TNFI+. ( 28934199 )
2017
48
In Vitro Immunomodulatory Activity of a Transition-State Analog Inhibitor of Human Purine Nucleoside Phosphorylase in Cutaneous Leishmaniasis. ( 28929123 )
2017
49
Leishmanicidal and Trypanocidal Activity of Metal Complexes with 1,2,4-Triazolo[1,5-a]pyrimidines: Insights on their Therapeutic Potential against Leishmaniasis and Chagas Disease. ( 28521698 )
2017
50
In Vitro and In Vivo Evaluation of Essential Oil from Artemisia absinthium L. Formulated in Nanocochleates against Cutaneous Leishmaniasis. ( 28930253 )
2017

Variations for Leishmaniasis

Expression for Leishmaniasis

Search GEO for disease gene expression data for Leishmaniasis.

Pathways for Leishmaniasis

Pathways related to Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.17 HLA-DRB1 IFNG IFNGR1 IL10 IL13 IL1A
2
Show member pathways
13.79 IFNG IFNGR1 IL10 IL13 IL1A IL1B
3
Show member pathways
13.65 IFNG IFNGR1 IL10 IL13 IL1A IL1B
4
Show member pathways
13.58 IL10 IL13 IL1A IL1B IL4 IL5
5
Show member pathways
13.52 HLA-DRB1 IFNG IFNGR1 IL10 IL13 IL1A
6
Show member pathways
13.39 HLA-DRB1 IFNG IFNGR1 IL1A IL1B IL4
7
Show member pathways
13.36 IL10 IL13 IL1A IL1B IL4 IL5
8
Show member pathways
13.11 IL1A IL1B NOS2 TLR2 TLR4 TLR9
9
Show member pathways
13.05 IFNG IFNGR1 IL10 IL1B NOS2 TLR2
10
Show member pathways
13.03 HLA-DRB1 HSPA4 IFNG IL10 IL13 IL1A
11
Show member pathways
12.96 HLA-DRB1 IFNG IFNGR1 IL13 IL1A IL1B
12
Show member pathways
12.82 IL1A IL1B TLR2 TLR4 TLR9 TNF
13
Show member pathways
12.76 HLA-DRB1 IFNG IFNGR1 IL10 IL4 TNF
14
Show member pathways
12.74 IFNG IFNGR1 IL1A IL1B TNF
15
Show member pathways
12.74 IL1A IL1B TLR2 TLR4 TLR9 TNF
16 12.73 IFNG IL10 IL1B IL4 TLR2 TLR9
17
Show member pathways
12.67 IFNG IL10 IL1B NOS2 TNF
18
Show member pathways
12.64 IFNG IL10 IL1A IL1B IL4 IL5
19
Show member pathways
12.57 HLA-DRB1 IFNG IFNGR1 IL10 IL13 IL1A
20
Show member pathways
12.54 IFNG IL13 IL1B IL4 IL5 TLR2
21
Show member pathways
12.48 IFNG IFNGR1 IL1A IL1B NOS2 TLR4
22
Show member pathways
12.41 IFNG IFNGR1 IL10 IL13 IL4 IL5
23 12.39 IFNG IFNGR1 NOS2 TLR2 TLR4 TLR9
24
Show member pathways
12.35 IFNG IL10 IL13 IL1A IL1B IL4
25 12.32 IL10 IL13 IL1A IL1B TNF
26
Show member pathways
12.27 IFNG IFNGR1 IL1B IL4 NOS2 TLR2
27
Show member pathways
12.24 IL13 IL1A IL1B IL5 TLR2 TLR4
28 12.22 HLA-DRB1 ITGAM TLR2 TLR4
29 12.22 IFNG IL10 IL4 IL5 ITGAM TNF
30 12.22 IFNG IL1A IL1B IL4 NOS2 TLR4
31 12.21 IFNG IFNGR1 IL1A IL1B TNF
32
Show member pathways
12.21 HLA-DRB1 IFNG IFNGR1 IL10 IL1A IL1B
33 12.18 IFNG IL1A IL1B TNF
34 12.17 IL10 IL13 IL1A IL1B IL4 ITGAM
35
Show member pathways
12.15 HLA-DRB1 IFNG IL1B IL4 NOS2
36
Show member pathways
12.14 IFNG IL1B IL4 TLR2 TLR4 TLR9
37
Show member pathways
12.13 IFNG IFNGR1 IL10 IL1B TLR2 TLR4
38 12.11 HLA-DRB1 IL1A IL1B IL4 IL5 ITGAM
39 12.07 HLA-DRB1 IFNG IL1A IL1B TLR2 TLR4
40 12.05 IFNG IFNGR1 IL1A IL1B NOS2 TLR4
41 12.03 IFNG IFNGR1 NOS2 TLR4
42 12.02 IFNG IL10 IL1B ITGAM NOS2 TLR2
43 11.99 HLA-DRB1 IFNG IFNGR1 IL10 IL1A IL1B
44 11.98 IFNG IL10 IL1B ITGAM TLR9 TNF
45 11.98 IL10 IL1A IL1B ITGAM NOS2 TLR4
46 11.95 ITGAM TLR2 TLR4 TLR9
47
Show member pathways
11.93 IFNG IFNGR1 IL1B
48 11.93 IFNG IL13 IL4 IL5
49
Show member pathways
11.9 IFNG IL4 IL5 TNF
50 11.88 IL13 IL1B IL4 IL5 TNF

GO Terms for Leishmaniasis

Cellular components related to Leishmaniasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 IFNG IL10 IL13 IL1A IL1B IL4
2 endosome membrane GO:0010008 9.46 HLA-DRB1 SLC11A1 TLR4 TLR9
3 external side of plasma membrane GO:0009897 9.1 HLA-DRB1 IFNG IL13 IL4 TLR4 TNF

Biological processes related to Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 92)
id Name GO ID Score Top Affiliating Genes
1 defense response to Gram-negative bacterium GO:0050829 9.98 NOS2 SLC11A1 TLR4 TLR9
2 response to lipopolysaccharide GO:0032496 9.98 IL10 IL13 IL1B NOS2 SLC11A1 TLR2
3 positive regulation of JNK cascade GO:0046330 9.97 IL1B TLR4 TLR9 TNF
4 regulation of insulin secretion GO:0050796 9.96 IFNG IL1B NOS2 TNF
5 cellular response to mechanical stimulus GO:0071260 9.94 IL13 IL1B TLR4
6 interferon-gamma-mediated signaling pathway GO:0060333 9.93 HLA-DRB1 IFNG IFNGR1
7 positive regulation of inflammatory response GO:0050729 9.93 TLR2 TLR4 TLR9
8 positive regulation of T cell proliferation GO:0042102 9.93 IFNG IL1B IL4
9 positive regulation of tumor necrosis factor production GO:0032760 9.93 IFNG TLR2 TLR4 TLR9
10 positive regulation of nitric oxide biosynthetic process GO:0045429 9.91 IFNG IL1B TLR4 TNF
11 positive regulation of interferon-gamma production GO:0032729 9.91 IL1B SLC11A1 TLR4 TNF
12 toll-like receptor signaling pathway GO:0002224 9.9 TLR2 TLR4 TLR9
13 lipopolysaccharide-mediated signaling pathway GO:0031663 9.89 IL1B TLR2 TLR4 TNF
14 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.88 IL1A IL1B TNF
15 response to bacterium GO:0009617 9.88 NOS2 SLC11A1 TLR4
16 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.88 IL1A IL1B IL4
17 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.88 TLR2 TLR4 TLR9
18 negative regulation of interleukin-6 production GO:0032715 9.88 IL10 TLR4 TLR9 TNF
19 positive regulation of interleukin-12 production GO:0032735 9.88 IFNG TLR2 TLR4 TLR9
20 positive regulation of phagocytosis GO:0050766 9.87 IL1B SLC11A1 TNF
21 negative regulation of endothelial cell apoptotic process GO:2000352 9.87 IL10 IL13 IL4
22 positive regulation of interleukin-10 production GO:0032733 9.87 IL4 TLR2 TLR4 TLR9
23 positive regulation of cytokine secretion GO:0050715 9.86 IL10 IL1A TNF
24 positive regulation of interferon-beta production GO:0032728 9.86 TLR2 TLR4 TLR9
25 negative regulation of interferon-gamma production GO:0032689 9.86 HLA-DRB1 IL10 TLR4
26 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.85 IFNG IL1B TNF
27 defense response to protozoan GO:0042832 9.85 IFNG IL10 IL4 SLC11A1
28 negative regulation of growth of symbiont in host GO:0044130 9.84 IFNG IL10 TNF
29 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.83 TLR2 TLR4 TLR9
30 response to molecule of bacterial origin GO:0002237 9.83 IL10 TLR2 TLR9
31 positive regulation of chemokine production GO:0032722 9.83 TLR2 TLR4 TLR9 TNF
32 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.82 IL10 IL1B TNF
33 I-kappaB phosphorylation GO:0007252 9.82 TLR2 TLR4 TLR9
34 regulation of cytokine secretion GO:0050707 9.81 TLR2 TLR4 TLR9
35 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.77 IL1A IL1B
36 positive regulation of podosome assembly GO:0071803 9.77 IL5 TNF
37 T-helper 1 type immune response GO:0042088 9.77 HLA-DRB1 TLR4
38 positive regulation of mast cell degranulation GO:0043306 9.76 IL13 IL4
39 negative regulation of interleukin-17 production GO:0032700 9.76 IFNG TLR4
40 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.76 IL1B TLR9
41 cellular response to lipoteichoic acid GO:0071223 9.76 TLR2 TLR4
42 positive regulation of isotype switching to IgG isotypes GO:0048304 9.76 IFNG IL4
43 macrophage activation GO:0042116 9.76 SLC11A1 TLR4
44 positive regulation of monocyte chemotactic protein-1 production GO:0071639 9.76 IL1A IL1B
45 regulation of defense response to virus by host GO:0050691 9.76 IFNG IL1B
46 positive regulation of B cell proliferation GO:0030890 9.76 IL13 IL4 IL5 TLR4
47 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.75 IFNG IL4
48 positive regulation of interleukin-6 biosynthetic process GO:0045410 9.75 IFNG IL1B
49 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.75 TLR4 TNF
50 endothelial cell apoptotic process GO:0072577 9.75 IL10 TNF

Molecular functions related to Leishmaniasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.23 IFNG IL10 IL13 IL1A IL1B IL4
2 lipopolysaccharide receptor activity GO:0001875 9.16 TLR2 TLR4
3 interleukin-1 receptor binding GO:0005149 9.13 IL1A IL1B TLR9

Sources for Leishmaniasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....